Stocks TelegraphStocks Telegraph
Stock Ideas

ST Premium

Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Try Now for Just $1!

OVID Company Profile and Key Details

NASDAQ : OVID

Ovid Therapeutics Inc.

$0.33
-0.0112-3.31%
At Close 4:00 PM
57.48
BESG ScoreESG Rating
ProfileKey StatsAnalyst RatingsOwnershipRatiosFinancialsDividend & splitsSentimentForecast

Price Chart

Stock Price Today

Ovid Therapeutics Inc. (OVID) stock declined over -3.31%, trading at $0.33 on NASDAQ, down from the previous close of $0.34. The stock opened at $0.33, fluctuating between $0.31 and $0.33 in the recent session.

Stock Snapshot

0.3383
Prev. Close
23.25M
Market Cap
0.3089
Day Low
-0.88
P/E Ratio
-0.37
EPS (TTM)
-0.65
Cash Flow per Share
0.33
Open
71.08M
Number of Shares
0.33
Day High
79.67%
Free Float in %
1.24
Book Value
459.13K
Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing DateAccepted Date

Annual Report (10-k)

Filing DateAccepted Date

Stock Price History Chart

DateOpenHighLowCloseVolume
Apr 30, 20250.330.330.310.33458.27K
Apr 29, 20250.350.360.330.34374.52K
Apr 28, 20250.350.360.340.35739.91K
Apr 25, 20250.350.350.320.35633.75K
Apr 24, 20250.350.360.320.34759.91K
Apr 23, 20250.320.330.300.33694.71K
Apr 22, 20250.290.300.280.29203.97K
Apr 21, 20250.290.290.270.29197.27K
Apr 17, 20250.280.290.270.29222.64K
Apr 16, 20250.290.300.260.27236.37K
Apr 15, 20250.280.300.280.29217.15K
Apr 14, 20250.300.300.280.29333.96K
Apr 11, 20250.280.300.260.28407.72K
Apr 10, 20250.280.320.250.26440.71K
Apr 09, 20250.260.300.240.28297.87K
Apr 08, 20250.310.310.260.26330.21K
Apr 07, 20250.290.300.260.29444.53K
Apr 04, 20250.320.320.280.28359.5K
Apr 03, 20250.330.340.300.30219.23K
Apr 02, 20250.330.350.320.34166.66K

Contact Details

New York, NY 10036

United States

https://www.ovidrx.com646 661 7661

About Company

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Company Information

Employees23
Beta0.44
Sales or Revenue$391.70K
5Y Sales Change%0%
Fiscal Year EndsDecember
SectorHealthcare
IndustryBiotechnology

Frequently Asked Questions

What is the current Ovid Therapeutics Inc. (OVID) stock price?
Ovid Therapeutics Inc. (NASDAQ: OVID) stock price is $0.33 in the last trading session. During the trading session, OVID stock reached the peak price of $0.33 while $0.31 was the lowest point it dropped to. The percentage change in OVID stock occurred in the recent session was -3.31% while the dollar amount for the price change in OVID stock was -$0.01.
OVID's industry and sector of operation?
The NASDAQ listed OVID is part of Biotechnology industry that operates in the broader Healthcare sector. Ovid Therapeutics Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of OVID?
Dr. Matthew J. During DSc, FACP, FRACP, M.D., Ph.D.
Founder & Member of Scientific Advisory Board
Dr. Claude Nicaise M.D.
Head of R&D
Mr. Jason Tardio M.B.A.
Chief Operating Officer
Dr. Dirk Haasner
Senior Vice President of Global Manufacturing & CMC QA
Ms. Suzanne K. Wakamoto SHRM-SCP, SPHR
Senior Vice President of Culture & Facilities
Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir
Pres, Chief Executive Officer & Chairman
Dr. Julia Tsai Ph.D.
Senior Vice President of Clinical Devel.
Mr. Simon D. Kelner
Chief HR Officer
Mr. Thomas Michael Perone J.D., M.B.A.
Gen. Counsel, Chief Compliance Officer & Corporation Sec.
Dr. Todd F. Baumgartner M.D., M.P.H.
Senior Vice President of Regulatory Affairs
Ms. Lora Pike
Vice President of Investor Relations & Communications
Dr. Todd F. Baumgartner M.P.H., M.D.
Senior Vice President of Regulatory Affairs, Pharmacovigilance & Biometrics
Mr. Jeffrey A. Rona
Principal Financial Officer, Principal Accounting Officer & Chief Bus. and Financial Officer
How OVID did perform over past 52-week?
OVID's closing price is 34.61% higher than its 52-week low of $0.24 where as its distance from 52-week high of $3.43 is -90.45%.
How many employees does OVID have?
Number of OVID employees currently stands at 23.
Link for OVID official website?
Official Website of OVID is: https://www.ovidrx.com
How do I contact OVID?
OVID could be contacted at phone 646 661 7661 and can also be accessed through its website. OVID operates from 1460 Broadway, New York, NY 10036, United States.
How many shares of OVID are traded daily?
OVID stock volume for the day was 459.13K shares. The average number of OVID shares traded daily for last 3 months was 391.89K.
What is the market cap of OVID currently?
The market value of OVID currently stands at $23.25M with its latest stock price at $0.33 and 71.08M of its shares outstanding.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

HomeAboutMeet The TeamContact UsPrivacy PolicyNewsletter

Useful Links

ScreenerMarket DataInsider TransactionsUpgrades & Downgrades52 Week Highs & LowsUnusual VolumeDividend CalendarEarnings Calendar
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph